Nanovibronix Inc Financials
Nanovibronix Inc (NAOV) reported $2.6M in revenue for fiscal year 2025, down 0.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 looks less like operating progress and more like a goodwill-heavy balance-sheet expansion masking a sharper cash drain.
With revenue roughly flat, gross profit fell from$1.5M to$153K , showing FY2025 pressure came from weaker unit economics rather than a simple volume reset. Because free cash flow of-$9.4M was almost the same as operating cash flow and capex was only$60K , the cash drain came from core operations; the larger asset base was also less liquid than it looked because much of it was goodwill.
The liquidity cushion has thinned from 4.4x in FY2021 to 1.1x in FY2025, which means losses are now being carried with far less room for timing slips in collections or inventory turnover. That helps explain why external financing still mattered even after the balance sheet became larger.
In FY2025, overhead outran scale: SG&A plus R&D totaled
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Nanovibronix Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nanovibronix Inc scores -4.59, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.2M) relative to total liabilities ($7.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nanovibronix Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Nanovibronix Inc reported a net loss of $18.2M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Nanovibronix Inc generated $2.6M in revenue in fiscal year 2025. This represents a decrease of 0.2% from the prior year.
Nanovibronix Inc's EBITDA was -$22.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 514.1% from the prior year.
Nanovibronix Inc reported -$18.2M in net income in fiscal year 2025. This represents a decrease of 390.8% from the prior year.
Cash & Balance Sheet
Nanovibronix Inc recorded an outflow of $9.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 274.4% from the prior year.
Nanovibronix Inc held $4.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Nanovibronix Inc's gross margin was 6.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 53.0 percentage points from the prior year.
Nanovibronix Inc's ROE was -54.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 536.6 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Nanovibronix Inc invested $1.8M in research and development in fiscal year 2025. This represents an increase of 93.8% from the prior year.
Nanovibronix Inc invested $60K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1900.0% from the prior year.
Not reported for fiscal year 2025.
NAOV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $2.6M-0.2% | $2.6M+12.0% | $2.3M+203.6% | $752K-55.6% | $1.7M+172.1% | $623K+17.5% | $530K+66.7% | $318K+33.1% | $239K+4.4% | $229K+55.8% | $147K-27.6% | $203K |
| Cost of Revenue | $2.5M | $2.4M+128.6% | $1.1M+40.8% | $746K+27.5% | $585K-36.8% | $925K+126.2% | $409K+64.3% | $249K+57.6% | $158K+79.5% | $88K0.0% | $88K+79.6% | $49K-47.3% | $93K |
| Gross Profit | -$271K | $153K-89.9% | $1.5M-1.9% | $1.5M+820.4% | $167K-78.3% | $770K+259.8% | $214K-23.8% | $281K+75.6% | $160K+6.0% | $151K+7.1% | $141K+43.9% | $98K-10.9% | $110K |
| R&D Expenses | $1.7M | $1.8M+93.8% | $909K+391.4% | $185K-34.6% | $283K-3.4% | $293K+71.3% | $171K-66.7% | $514K-16.3% | $614K-11.4% | $693K+18.7% | $584K+46.4% | $399K-7.4% | $431K |
| SG&A Expenses | $8.7M | $7.6M+120.5% | $3.5M-11.8% | $3.9M-0.2% | $3.9M-22.3% | $5.1M+34.2% | $3.8M-1.4% | $3.8M+44.9% | $2.6M+26.5% | $2.1M+53.3% | $1.4M+82.2% | $746K+26.7% | $589K |
| Operating Income | -$24.7M | -$22.9M-539.0% | -$3.6M-4.2% | -$3.4M+31.4% | -$5.0M+11.8% | -$5.7M-20.4% | -$4.7M+8.4% | -$5.2M-19.7% | -$4.3M-39.2% | -$3.1M-33.5% | -$2.3M-62.6% | -$1.4M-17.6% | -$1.2M |
| Interest Expense | N/A | N/A | $135K0.0% | $135K-61.1% | $347K | N/A | $147K+880.0% | $15K | N/A | $37K | $0-100.0% | $65K-82.5% | $372K |
| Income Tax | -$289K | -$307K-1715.8% | $19K-34.5% | $29K-17.1% | $35K+9.4% | $32K+113.3% | $15K+188.2% | -$17K+86.6% | -$127K-434.2% | $38K-67.5% | $117K+317.9% | $28K-42.9% | $49K |
| Net Income | -$20.1M | -$18.2M-390.8% | -$3.7M+0.2% | -$3.7M+31.9% | -$5.4M+61.9% | -$14.3M-230.1% | -$4.3M+25.3% | -$5.8M-39.5% | -$4.2M+16.3% | -$5.0M | N/A | -$2.9M-9.0% | -$2.6M |
| EPS (Diluted) | — | -$26.69 | -$137.30 | -$23.32 | -$3.84 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NAOV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $41.1M+1033.2% | $3.6M-45.6% | $6.7M+13.5% | $5.9M-31.8% | $8.6M+4.8% | $8.2M+304.2% | $2.0M+28.9% | $1.6M-67.5% | $4.9M+884.8% | $494K-75.1% | $2.0M+174.3% | $723K |
| Current Assets | $7.3M+118.3% | $3.3M-48.7% | $6.5M+15.7% | $5.6M-32.8% | $8.3M+4.7% | $8.0M+333.6% | $1.8M+49.4% | $1.2M-72.8% | $4.5M+1945.7% | $221K-87.6% | $1.8M+976.4% | $165K |
| Cash & Equivalents | $4.2M+461.7% | $752K-77.1% | $3.3M+21.0% | $2.7M-64.9% | $7.7M+8.3% | $7.1M+433.8% | $1.3M+49.3% | $896K-79.4% | $4.4M+4013.2% | $106K-93.4% | $1.6M+1693.3% | $90K |
| Inventory | $2.3M+6.7% | $2.2M-19.8% | $2.7M+25.6% | $2.2M+1142.9% | $175K+20.7% | $145K+19.8% | $121K-16.0% | $144K+89.5% | $76K+13.4% | $67K-5.6% | $71K+102.9% | $35K |
| Accounts Receivable | $289K+194.9% | $98K-69.2% | $318K+3433.3% | $9K-95.5% | $200K+700.0% | $25K-77.5% | $111K+16.8% | $95K+295.8% | $24K+300.0% | $6K+20.0% | $5K-76.2% | $21K |
| Goodwill | $29.1M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.6M+154.1% | $3.0M+11.8% | $2.7M+1.5% | $2.6M+14.6% | $2.3M-60.4% | $5.8M+748.1% | $688K-38.4% | $1.1M-9.3% | $1.2M-58.9% | $3.0M+36.5% | $2.2M-65.4% | $6.3M |
| Current Liabilities | $6.7M+144.7% | $2.7M+10.9% | $2.5M+6.0% | $2.3M+21.7% | $1.9M-34.4% | $2.9M+609.5% | $409K-36.1% | $640K-19.7% | $797K+41.1% | $565K+90.2% | $297K-94.5% | $5.4M |
| Total Equity | $33.5M+5242.4% | $627K-84.3% | $4.0M+23.4% | $3.2M-48.8% | $6.3M+163.7% | $2.4M+77.7% | $1.3M+190.9% | $463K-87.3% | $3.6M+245.4% | -$2.5M-1095.7% | -$209K+96.3% | -$5.6M |
| Retained Earnings | -$90.5M-29.6% | -$69.8M-5.6% | -$66.1M-5.9% | -$62.4M-9.6% | -$56.9M-33.5% | -$42.7M-11.3% | -$38.3M-17.8% | -$32.5M-14.6% | -$28.4M-25.7% | -$22.6M-14.4% | -$19.7M-17.1% | -$16.9M |
Not reported in any period shown, so not listed: Long-Term Debt.
NAOV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.3M | -$9.4M-272.5% | -$2.5M+30.1% | -$3.6M+48.8% | -$7.0M-61.1% | -$4.4M-28.8% | -$3.4M+12.5% | -$3.9M-9.1% | -$3.5M-62.7% | -$2.2M-42.3% | -$1.5M-3.6% | -$1.5M-64.4% | -$900K |
| Capital Expenditures | $72K | $60K+1900.0% | $3K+200.0% | $1K-66.7% | $3K0.0% | $3K+50.0% | $2K | N/A | $8K | N/A | $8K+700.0% | $1K-75.0% | $4K |
| Free Cash Flow | -$12.4M | -$9.4M-274.4% | -$2.5M+30.1% | -$3.6M+48.8% | -$7.0M-61.1% | -$4.4M-28.8% | -$3.4M | N/A | -$3.6M | N/A | -$1.5M-4.1% | -$1.5M-63.8% | -$904K |
| Investing Cash Flow | -$72K | $88K+3033.3% | -$3K-200.0% | -$1K+66.7% | -$3K0.0% | -$3K-50.0% | -$2K | N/A | -$8K | N/A | -$8K | N/A | N/A |
| Financing Cash Flow | $14.1M | $12.8M+1278500.0% | $1K-100.0% | $4.2M+101.8% | $2.1M-54.3% | $4.6M-51.9% | $9.5M+120.6% | $4.3M+4491.5% | $94K-98.5% | $6.4M+19403.0% | $33K | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NAOV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 6.0%-53.0pp | 59.0%-8.4pp | 67.3%+45.1pp | 22.2%-23.2pp | 45.4%+11.1pp | 34.4%-18.7pp | 53.0%+2.7pp | 50.3%-12.9pp | 63.2%+1.6pp | 61.6%-5.1pp | 66.7%+12.5pp | 54.2% |
| Operating Margin | -896.6% | -140.0% | -150.5% | -666.5% | -335.3% | -757.5% | -971.9% | -1353.1% | -1293.3% | -1011.4% | -968.7% | -596.5% |
| Net Margin | -712.3% | -144.8% | -162.5% | -724.5% | -842.6% | -694.4% | -1093.2% | -1306.3% | -2077.4% | N/A | -1961.9% | -1303.9% |
| Return on Equity | -54.3%+536.6pp | -590.9%-497.9pp | -93.0%+75.5pp | -168.5%+57.7pp | -226.2%-45.5pp | -180.7%+249.4pp | -430.1%+467.0pp | -897.2%-760.6pp | -136.6% | N/A | N/A | N/A |
| Return on Assets | -44.2%+57.9pp | -102.1%-46.5pp | -55.6%+37.1pp | -92.7%+73.0pp | -165.7%-113.1pp | -52.6%+232.0pp | -284.6%-21.7pp | -262.9%-160.9pp | -102.1% | N/A | -145.4%+220.7pp | -366.1% |
| Current Ratio | 1.09-0.1x | 1.22-1.4x | 2.64+0.2x | 2.42-2.0x | 4.38+1.6x | 2.75-1.7x | 4.49+2.6x | 1.92-3.8x | 5.67+5.3x | 0.39-5.6x | 5.98+5.9x | 0.03 |
| Debt-to-Equity | 0.23-4.6x | 4.79+4.1x | 0.67-0.1x | 0.82+0.5x | 0.37-2.1x | 2.44+1.9x | 0.51-1.9x | 2.41+2.1x | 0.34 | N/A | N/A | N/A |
| FCF Margin | -369.4% | -98.5% | -157.8% | -935.9% | -257.8% | -544.6% | N/A | -1118.9% | N/A | -672.9% | -1007.5% | -445.3% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Nanovibronix Inc Ranks
Frequently Asked Questions
What is Nanovibronix Inc's annual revenue?
Nanovibronix Inc (NAOV) reported $2.6M in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nanovibronix Inc's revenue growing?
Nanovibronix Inc (NAOV) revenue declined by 0.2% year-over-year, from $2.6M to $2.6M in fiscal year 2025.
Is Nanovibronix Inc profitable?
No, Nanovibronix Inc (NAOV) reported a net income of -$18.2M in fiscal year 2025.
What is Nanovibronix Inc's EBITDA?
Nanovibronix Inc (NAOV) had EBITDA of -$22.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nanovibronix Inc's gross margin?
Nanovibronix Inc (NAOV) had a gross margin of 6.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Nanovibronix Inc's return on equity (ROE)?
Nanovibronix Inc (NAOV) has a return on equity of -54.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nanovibronix Inc's free cash flow?
Nanovibronix Inc (NAOV) recorded an outflow of $9.4M in free cash flow during fiscal year 2025. This represents a -274.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nanovibronix Inc's operating cash flow?
Nanovibronix Inc (NAOV) recorded an outflow of $9.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Nanovibronix Inc's total assets?
Nanovibronix Inc (NAOV) had $41.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nanovibronix Inc's capital expenditures?
Nanovibronix Inc (NAOV) invested $60K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nanovibronix Inc spend on research and development?
Nanovibronix Inc (NAOV) invested $1.8M in research and development during fiscal year 2025.
What is Nanovibronix Inc's current ratio?
Nanovibronix Inc (NAOV) had a current ratio of 1.09 as of fiscal year 2025, which is considered adequate.
What is Nanovibronix Inc's debt-to-equity ratio?
Nanovibronix Inc (NAOV) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nanovibronix Inc's return on assets (ROA)?
Nanovibronix Inc (NAOV) had a return on assets of -44.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nanovibronix Inc's cash runway?
Based on fiscal year 2025 data, Nanovibronix Inc (NAOV) had $4.2M in cash against an annual operating cash burn of $9.4M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Nanovibronix Inc's Altman Z-Score?
Nanovibronix Inc (NAOV) has an Altman Z-Score of -4.59, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nanovibronix Inc's Piotroski F-Score?
Nanovibronix Inc (NAOV) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nanovibronix Inc's earnings high quality?
Nanovibronix Inc (NAOV) reported a net loss of $18.2M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Nanovibronix Inc?
Nanovibronix Inc (NAOV) scores 32 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.